Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ImmunoCellular Therapeutics Ltd (NYSE MKT LLC:IMUC)

0.1255
Delayed Data
As of 3:59pm ET
 -0.0025 / -1.95%
Today’s Change
0.12
Today|||52-Week Range
0.59
-64.68%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$16.4M

Company Description

ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that develops immune-based therapies for the treatment of brain and other cancers. ImmunoCellular's pipeline includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.

Contact Information

ImmunoCellular Therapeutics Ltd.
23622 Calabasas Road
Calabasas California 91302
P:(818) 264-2300
Investor Relations:

Employees

Shareholders

Other institutional9.85%
Mutual fund holders3.85%
Individual stakeholders1.87%

Top Executives

Andrew GengosPresident, Chief Executive Officer & Director
David E. FractorPrincipal Financial & Accounting Officer
Steven J. SwansonSenior Vice President-Research
John S. YuSecretary & Director
Anthony J. GringeriSenior Vice President-Strategic Resources